(via NewsDirect)
Best Growth Stock's full report breaks through the noise and offers a full comprehensive and easy-to-understand analysis of Avalo’s securities, recent events, earnings, pipeline, and more.
Access this full report: https://bestgrowthstocks.com/access-avtx-analysis/ (copy and paste to browser may be required)
About Avalo Therapeutics
LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.
Avalo has an experienced leadership team with decades of successful leadership in drug development in the biotech and pharma industries. The team is led by Dr.
For more information about Avalo, please visit https://www.avalotx.com/.
Investor Inquiries
ir@avalotx.com
410-803-6793
About Best Growth Stocks
Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. Not to be construed as financial advice. Consult with a licensed financial advisor prior to any financial decisions.
Media Contact
Best Growth Stocks
Steve Macalbry, Senior Editor
Editor@BestGrowthStocks.com
SOURCE: BestGrowthStocks.Com
Contact Details
Best Growth Stocks
Steve Macalbry
Editor@bestgrowthstocks.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source